{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:51:50Z","timestamp":1789829510312,"version":"4.0.1"},"reference-count":24,"publisher":"e-Century Publishing Corporation","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/nvfb3780","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T03:10:42Z","timestamp":1725937842000},"page":"3896-3904","source":"Crossref","is-referenced-by-count":12,"title":["Personalized mRNA vaccine combined with PD-1 inhibitor therapy in a patient with advanced esophageal squamous cell carcinoma"],"prefix":"10.62347","volume":"14","author":[{"given":"Bin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.soc.2022.07.006","article-title":"The perioperative and operative management of esophageal and gastric cancer","volume":"32","author":"Siddiqi","year":"2023","unstructured":"Siddiqi A and Johnston FM. The perioperative and operative management of esophageal and gastric cancer. Surg Oncol Clin N Am 2023; 32: 65-81.","journal-title":"Surg Oncol Clin N Am"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/JS9.0000000000000816","article-title":"Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis","volume":"110","author":"Xu","year":"2024","unstructured":"Xu J, Cai Y, Hong Z, Duan H and Ke S. Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. Int J Surg 2024; 110: 490-506.","journal-title":"Int J Surg"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"612451","DOI":"10.3389\/fcell.2021.612451","article-title":"Mechanisms of pharmaceutical therapy and drug resistance in esophageal cancer","volume":"9","author":"Mao","year":"2021","unstructured":"Mao C, Zeng X, Zhang C, Yang Y, Xiao X, Luan S, Zhang Y and Yuan Y. Mechanisms of pharmaceutical therapy and drug resistance in esophageal cancer. Front Cell Dev Biol 2021; 9: 612451.","journal-title":"Front Cell Dev Biol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fbioe.2020.00019","article-title":"Engineering targeting materials for therapeutic cancer vaccines","volume":"8","author":"Briquez","year":"2020","unstructured":"Briquez PS, Hauert S, de Titta A, Gray LT, Alpar AT, Swartz MA and Hubbell JA. Engineering targeting materials for therapeutic cancer vaccines. Front Bioeng Biotechnol 2020; 8: 19.","journal-title":"Front Bioeng Biotechnol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejca.2020.01.010","article-title":"Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer","volume":"129","author":"Zamani","year":"2020","unstructured":"Zamani P, Teymouri M, Nikpoor AR, Navashenaq JG, Gholizadeh Z, Darban SA and Jaafari MR. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer. Eur J Cancer 2020; 129: 80-96.","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00281-023-00986-4","article-title":"Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16","volume":"45","author":"CJM","year":"2023","unstructured":"Melief CJM, van der Gracht E and Wiekmeijer AS. Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16. Semin Immunopathol 2023; 45: 273-277.","journal-title":"Semin Immunopathol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"114062","DOI":"10.1016\/j.biopha.2022.114062","article-title":"Current advances in the application of nanomedicine in bladder cancer","volume":"157","author":"Zhang","year":"2023","unstructured":"Zhang C, Zhao J, Wang W, Geng H, Wang Y and Gao B. Current advances in the application of nanomedicine in bladder cancer. Biomed Pharmacother 2023; 157: 114062.","journal-title":"Biomed Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","article-title":"Cancer vaccines: building a bridge over troubled waters","volume":"185","author":"MC","year":"2022","unstructured":"Sellars MC, Wu CJ and Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell 2022; 185: 2770-2788.","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1200\/JCO.2008.20.6789","article-title":"Concurrent trastuzumab and HER2\/neu-specific vaccination in patients with metastatic breast cancer","volume":"27","author":"Disis","year":"2009","unstructured":"Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Link J, Waisman J and Salazar LG. Concurrent trastuzumab and HER2\/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27: 4685-92.","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","unstructured":"Chang K and Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996; 93: 136-40.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1586\/14760584.4.4.493","article-title":"MUC1 as a target antigen for cancer immunotherapy","volume":"4","author":"Acres","year":"2005","unstructured":"Acres B and Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005; 4: 493-502.","journal-title":"Expert Rev Vaccines"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"9749363","DOI":"10.1155\/2022\/9749363","article-title":"Development of peptide-based vaccines for cancer","volume":"2022","author":"Abd-Aziz","year":"2022","unstructured":"Abd-Aziz N and Poh CL. Development of peptide-based vaccines for cancer. J Oncol 2022; 2022: 9749363.","journal-title":"J Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","unstructured":"Miao L, Zhang Y and Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer 2021; 20: 41.","journal-title":"Mol Cancer"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Liu J, Zhou WY, Luo XJ, Chen YX, Wong CW, Liu ZX, Bo Zheng J, Yu Mo H, Chen JQ, Li JJ, Zhong M, Xu YH, Zhang QH, Pu HY, Wu QN, Jin Y, Wang ZX, Xu RH and Luo HY. Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma. Clin Transl Med 2023; 13: e1410.","DOI":"10.1002\/ctm2.1410"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/postgradmedj-2021-140029","article-title":"Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients","volume":"98","author":"Liu","year":"2022","unstructured":"Liu Z, Sun L, Cai L, Guo M, Xu G, Liu S, Zheng G, Wang Q, Lian X, Feng F and Zhang H. Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients. Postgrad Med J 2022; 98: 948-957.","journal-title":"Postgrad Med J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/oncolo\/oyac187","article-title":"Application of value framework to phase III trials of immune checkpoint inhibitors in esophageal and gastric cancer","volume":"28","author":"Thawani","year":"2023","unstructured":"Thawani R, Agrawal N, Taflin NF, Kardosh A and Chen EY. Application of value framework to phase III trials of immune checkpoint inhibitors in esophageal and gastric cancer. Oncologist 2023; 28: 40-47.","journal-title":"Oncologist"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14712598.2017.1315404","article-title":"Promising immunotherapies for esophageal cancer","volume":"17","author":"Tanaka","year":"2017","unstructured":"Tanaka T, Nakamura J and Noshiro H. Promising immunotherapies for esophageal cancer. Expert Opin Biol Ther 2017; 17: 723-733.","journal-title":"Expert Opin Biol Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/nm1016-1192d","article-title":"Corrigendum: high-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"22","author":"Linnemann","year":"2016","unstructured":"Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, El Atmioui D, Visser M, Stratton MR, Haanen JB, Spits H, van der Burg SH and Schumacher TN. Corrigendum: high-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2016; 22: 1192.","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","unstructured":"Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, Tadmor AD, Schoenberger SP, Huber C, Türeci Ö and Sahin U. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520: 692-6.","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12865-021-00440-w","article-title":"Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases","volume":"22","author":"Achinko","year":"2021","unstructured":"Achinko DA, Dormer A, Narayanan M and Norman EF. Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases. BMC Immunol 2021; 22: 49.","journal-title":"BMC Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"114046","DOI":"10.1016\/j.addr.2021.114046","article-title":"Tumor associated macrophage and microbe: the potential targets of tumor vaccine delivery","volume":"180","author":"Jiang","year":"2022","unstructured":"Jiang J, Mei J, Yi S, Feng C, Ma Y, Liu Y, Liu Y and Chen C. Tumor associated macrophage and microbe: the potential targets of tumor vaccine delivery. Adv Drug Deliv Rev 2022; 180: 114046.","journal-title":"Adv Drug Deliv Rev"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"973601","DOI":"10.3389\/fimmu.2022.973601","article-title":"Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: a review of current developments","volume":"13","author":"Jiang","year":"2022","unstructured":"Jiang Q, Xie M, Chen R, Yan F, Ye C, Li Q, Xu S, Wu W, Jia Y, Shen P and Ruan J. Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: a review of current developments. Front Immunol 2022; 13: 973601.","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1341584","DOI":"10.3389\/fimmu.2023.1341584","article-title":"Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)","volume":"14","author":"Wang","year":"2024","unstructured":"Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, Liu W, Wu Y, Lv J, Feng Q, Zhou Z, Wang J, Wang L, Wang Z and Bi N. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study). Front Immunol 2024; 14: 1341584.","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jds.2023.09.006","article-title":"Evaluation of neck control strategies for oral squamous cell carcinoma of stage I: neck dissection or potential immunotherapy","volume":"19","author":"Yang","year":"2024","unstructured":"Yang C, Wang Z, Shi L and Liu W. Evaluation of neck control strategies for oral squamous cell carcinoma of stage I: neck dissection or potential immunotherapy. J Dent Sci 2024; 19: 640-644.","journal-title":"J Dent Sci"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/8\/ajcr0158336.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:54:54Z","timestamp":1766022894000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/8\/ajcr0158336.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/nvfb3780","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}